CAPTRUST Financial Advisors
VTYX

CAPTRUST Financial Advisors’s Ventyx Biosciences VTYX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36
Closed – – 4035
2022
Q2 		$0 Hold
36
– – ﹤0.01% 5164
2022
Q1 		$0 Buy
+36
New +$481 ﹤0.01% 5149

Other funds holding VTYX

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's VTYX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Ventyx Biosciences (VTYX) in Q3 2022, closing a stake of 36 shares.

CAPTRUST Financial Advisors first reported a position in VTYX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 104 funds tracked by Wall St. Rank hold VTYX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Ventyx Biosciences position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 36 Ventyx Biosciences shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Ventyx Biosciences in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Ventyx Biosciences position peaked at $0 in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.